Longevity Science

The Next Generation
of NAD+ Therapy

Niagen® (NR) IV delivers superior tolerability, faster infusions, and more rapid cellular NAD+ elevation than traditional NAD+ IV—backed by the first randomized clinical trial of its kind.

⏱️ 4 min read
March 2026
Peer-Reviewed Research
Niagen NR vs NAD+ IV therapy comparison for next-generation longevity treatments at Beyond Remedi Scottsdale
NR
75% Faster Infusion
20% NAD+ Rise at 3h
0 Inflammatory Response

NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme present in every living cell, essential for converting nutrients into cellular energy (ATP) and activating sirtuins—the proteins that govern DNA repair, inflammation control, and biological aging. Without adequate NAD+, cells lose the ability to maintain and repair themselves efficiently.

Research consistently demonstrates that NAD+ levels decline by up to 50% between our 40s and 60s. This decline is directly linked to fatigue, metabolic slowdown, cognitive fog, and the accelerated progression of age-related conditions. Replenishing NAD+ through intravenous therapy has emerged as one of the most direct and effective interventions in modern longevity medicine.

Why NAD+ Levels Decline With Age

NAD+ is not merely a metabolic cofactor—it is a master regulator of cellular health, governing energy production, DNA integrity, and the biological clock of aging.

While traditional NAD+ IV infusions have been used for years, they come with a well-documented set of limitations: lengthy sessions lasting two to four or more hours, and a significant side-effect profile including nausea, chest tightness, stomach cramping, and anxiety. These barriers have led researchers to investigate a more efficient delivery pathway—enter Nicotinamide Riboside (NR), the precursor molecule commercially known as Niagen®.

Niagen IV vs. Traditional NAD+ IV

The first randomized, placebo-controlled pilot study to directly compare these two therapies revealed clear, clinically meaningful differences across every key metric.[1]

Niagen® (NR) IV
Pharmaceutical-Grade Precursor
Infusion Time 30 – 60 minutes average
Tolerability High — mild, transient tingling only
NAD+ Elevation +20% at 3 hours post-infusion
Immune Response No inflammatory markers detected
Mechanism Intracellular NAD+ synthesis via NRK pathway
VS
Traditional NAD+ IV
Direct Extracellular Administration
Infusion Time 2 – 4+ hours (rate-limited by discomfort)
Tolerability Low — nausea, chest tightness, cramping, anxiety
NAD+ Elevation Peak delayed to 24 hours – 14 days
Immune Response Elevated WBC count — possible inflammatory signal
Mechanism Extracellular NAD+ interpreted as cellular damage
⏱️
Dramatically Faster Sessions Niagen IV completes up to 75% faster than NAD+ IV
30 – 60 min vs. 2 – 4+ hours
🛡️
Superior Tolerability Minimal side effects — no nausea, cramping, or chest pressure
Mild tingling only
Rapid NAD+ Elevation Blood NAD+ rises 20% within 3 hours — outperforming NAD+ IV
+20% at 3 hours post-infusion
🧬
No Inflammatory Response Intracellular pathway avoids immune misinterpretation
Zero WBC elevation

The Biology Behind Niagen's Advantage

Understanding why NR outperforms direct NAD+ administration requires a closer look at how cells actually absorb and utilize these molecules.

🔬 The Precursor Advantage
NAD+ is a large molecule that cannot easily cross the cell membrane directly. Niagen (NR), as a smaller precursor, enters cells efficiently via nicotinamide riboside kinase (NRK) transporters, where it is rapidly converted into NAD+ intracellularly. This pathway is more physiologically natural and avoids the extracellular accumulation that triggers immune responses.[1]
🔥 Why NAD+ IV Causes Discomfort
When NAD+ is administered directly into the bloodstream, the body detects elevated extracellular NAD+ as a signal of cellular damage or stress—a biological alarm system. This triggers an immune response, elevating white blood cell counts and producing the characteristic nausea, chest tightness, and cramping that patients experience during traditional NAD+ infusions.[2]
🧠 Sirtuin Activation & Longevity
Elevated intracellular NAD+ directly activates sirtuins (SIRT1, SIRT3), the enzymes that regulate DNA repair, mitochondrial biogenesis, and inflammation suppression. By safely and rapidly raising intracellular NAD+, Niagen IV unlocks these longevity pathways more efficiently than oral supplementation or traditional IV methods.
📊 Clinical Evidence
The 2024 randomized, placebo-controlled pilot study by Hawkins et al. is the first of its kind to directly compare Niagen IV and NAD+ IV in healthy adults. Results showed NR IV achieved a 20.7% increase in blood NAD+ at 3 hours, statistically outperforming both NAD+ IV and oral NR (p < 0.01), with no clinically meaningful changes in blood chemistry markers.[1]
Niagen safely increases intracellular NAD+ levels without triggering the inflammatory immune response often associated with direct extracellular NAD+ administration.
Hawkins et al., medRxiv 2024 — Pilot RCT

The Beyond Remedi Advantage

Pharmaceutical-grade Niagen IV is a newly patented innovation by Niagen Bioscience (formerly ChromaDex), and it is only available at a select number of premier wellness clinics across the country. This is not a therapy you can find at every IV bar or wellness center.

At Beyond Remedi, we have been partnered with Niagen since the very beginning. As early adopters of this breakthrough longevity protocol, our expert clinicians have accumulated the specialized experience and clinical knowledge required to administer Niagen IV for maximum efficacy and safety. Our protocols are not generic—they are individually tailored, medically supervised, and grounded in the latest peer-reviewed research.

When you choose Beyond Remedi for your Niagen infusion, you are not simply receiving a treatment—you are accessing one of the most advanced, comfortable, and clinically validated cellular optimization therapies available anywhere today.

Research References

  • Hawkins J, et al. Randomized, placebo-controlled, pilot clinical study evaluating acute Niagen®+ IV and NAD+ IV in healthy adults. medRxiv. 2024. medRxiv →
  • Reyna K, et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Frontiers in Aging. 2026. PMC →

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. IV therapy should only be pursued under the supervision of a licensed healthcare provider. Claims regarding benefits are based on current clinical research and may not apply universally. Always consult a qualified physician before beginning any new treatment.